Studies brain and muscle function in adults with Becker muscular dystrophy
Compares brain imaging, thinking tests and muscle function in adults with Becker muscular dystrophy.
Plain-language title generated from the registry record
Registry title: Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function
Key facts
- Where
- Paris, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07740057, who can take part
Where in France
- Institute of MythologyParis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut de Myologie, France
- Trial code
- NCT07740057
- Record updated
- 3 November 2026
- Original description
Monitoring patients with neuromuscular disorders is crucial but doesn't always allow for a sufficiently specific approach to all aspects of the condition. However, in the event of future treatment, it is essential for clinical and research teams to have as much information as possible about the disease, particularly regarding its physical, physiological, biological, and neurological aspects.Read full original descriptionShow less
Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function
Monitoring patients with neuromuscular disorders is crucial but doesn't always allow for a sufficiently specific approach to all aspects of the condition. However, in the event of future treatment, it is essential for clinical and research teams to have as much information as possible about the disease, particularly regarding its physical, physiological, biological, and neurological aspects.
In this context, it was consider as vital to investigate in greater depth the links between the presence of certain dystrophin isoforms in patients and their potential impacts on cognitive, neurological, and muscular function. The results of this study could serve as a reference for future research and improve the understanding and management of this disease.
All of this data will allow for a precise evaluation of the effects of a potential treatment on the progression of the disease.
Inclusion: Genetically confirmed diagnosis of Becker muscular dystrophy; Ambulant; Signed ICF.
Exclusion: History of allergy to contrast product; Individuals with history of neurological diseases interfering with the study; Individuals who are not yet or insufficiently stabilized on psychiatric medication; Any medical and social condition that may interfere with the study at the discretion of the medical coordinator; Individuals with concomitant medical conditions that could interfere with the study outcomes; subjects who suffer from any type of cancer (or on cancer treatment); obese subjects: BMI>35; subjects with cardiac (left-ventricular ejection fraction <40%) and/or respiratory insufficiency (forced vital capacity < 50%) and/or normal ECG; Individuals presenting contraindications to MRI; Guardianship.